Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faldaprevir + deleobuvir
- Development stage
- Discontinued
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Faldaprevir + deleobuvir is an oral fixed-dose combination evaluated for the treatment of chronic hepatitis C virus (HCV) infection, specifically genotype 1. Faldaprevir is an NS3/4A protease inhibitor, while deleobuvir is a non-nucleoside NS5B polymerase inhibitor. The combination is usually administered with ribavirin but is studied as an interferon-free regimen. Developed by Boehringer Ingelheim, the combination aimed to provide an effective oral therapy for HCV with improved tolerability over peginterferon-based regimens. However, efficacy was notably higher in HCV genotype 1b compared to genotype 1a patients, and the overall effectiveness did not surpass newer direct-acting antiviral regimens. As a result, further development of this combination regimen was terminated[3][2].
- Other names
- deleobuvir + faldaprevirBI 207127 + BI 201335
02
Targets
ABCC2 (ATP-binding cassette sub-family C member 2)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)UGT1A1 (UDP-glucuronosyltransferase 1A1)CYP3A4 (Cytochrome P450 3A4)SLCO1B3 (Organic anion transporting polypeptide 1B3)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)OATP1B1 (Organic anion transporting polypeptide 1B1)
Beyond the preview
Go deeper on faldaprevir + deleobuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faldaprevir + deleobuvir.